Qsymia Weight-Loss Doctor NYC

At a glance: Qsymia is an FDA-approved, once-daily extended-release combination of phentermine and topiramate for chronic weight management in eligible patients, alongside reduced-calorie nutrition and activity.

Choosing a medication is not a popularity contest. W8MD reviews weight history, blood pressure and pulse, current medicines, pregnancy potential, sleep, eating pattern, prior response, adverse effects, insurance rules, budget and long-term goals before discussing Qsymia.

Why formulation matters

Qsymia is a specific extended-release product with labeled titration and stopping rules. It should not be assumed equivalent to taking immediate-release phentermine and topiramate separately. See our formulation comparison.

Key safety considerations

• Qsymia can cause fetal harm. Pregnancy testing and effective contraception are important for patients who can become pregnant.
• Monitoring may include heart rate and laboratory review such as bicarbonate, creatinine and potassium.
• Mood changes, cognitive effects, metabolic acidosis, kidney stones, decreased sweating and acute eye symptoms require attention.
• Higher-dose treatment must be tapered as directed rather than stopped abruptly.

How W8MD compares options

The choice may turn on blood pressure, migraine history, pregnancy plans, kidney-stone risk, mood history, ability to tolerate injections and insurance. Compare Qsymia vs Wegovy and Zepbound.

Official source: current Qsymia labeling on DailyMed. See phentermine/topiramate.